NeuroNOS

Company Overview

Snapshot

Founded in March 2024 by Haitham Amal, NeuroNOS operates with 1–10 employees. The company was acquired by XTL Biopharmaceuticals in January 2026, marking a significant milestone in its development of therapies for neurological disorders.

Business overview

NeuroNOS is a biotechnology company focused on developing mechanism-based therapies for neurological disorders, with an initial focus on autism spectrum disorder (ASD). The company's approach is based on research identifying dysregulation of neuronal nitric oxide (nNOS) as a key biological driver of ASD, affecting synaptic function, oxidative stress, and brain metabolism. NeuroNOS is advancing a selective nNOS-targeted small molecule, supported by preclinical data, and has received FDA Orphan Drug Designation. It operates within the Health Tech & Life Sciences sector, specifically in Pharma & Medical Biotechnology and Drugs Discovery & Development.

Strategic signal

In January 2026, XTL Biopharmaceuticals acquired 85% of NeuroNOS, a subsidiary of Beyond Air. This acquisition signals a strategic entry into the autism market for XTL Biopharmaceuticals, leveraging NeuroNOS's novel treatment approach and scientific leadership. For investors, this indicates a validation of NeuroNOS's therapeutic potential and a significant step towards advancing its nNOS-targeted small molecule into clinical trials.

Company Intelligence Q&A

What was a significant corporate development for NeuroNOS in early 2026?

In January 2026, NeuroNOS was acquired by XTL Biopharmaceuticals. This acquisition involved XTL Biopharmaceuticals acquiring 85% of NeuroNOS, which was a subsidiary of Beyond Air.

What is NeuroNOS's primary focus in drug development?

NeuroNOS is focused on developing mechanism-based therapies for neurological disorders, with an initial emphasis on autism spectrum disorder (ASD).

What is the scientific basis for NeuroNOS's therapeutic approach?

NeuroNOS's approach is based on research indicating that dysregulation of neuronal nitric oxide (nNOS) is a key biological driver of ASD, impacting synaptic function, oxidative stress, and brain metabolism.

Has NeuroNOS received any regulatory designations for its lead candidate?

Yes, NeuroNOS has received FDA Orphan Drug Designation for its selective nNOS-targeted small molecule.

When was NeuroNOS founded and by whom?

NeuroNOS was founded in March 2024 by Haitham Amal, who serves as Co-founder & CSO.